Allergy Immunotherapy Market Outlook 2036: Market to Reach USD 6.6 Billion by 2036 at 8.1% CAGR – TMR

The global allergy immunotherapy market is entering a period of sustained expansion as the prevalence of allergic diseases rises worldwide and healthcare providers increasingly focus on long-term, disease-modifying treatment approaches. The market was valued at approximately USD 2.8 billion in 2025 and is projected to reach USD 6.6 billion by 2036, expanding at a CAGR of 8.1% from 2026 to 2036.

Allergy immunotherapy works by administering gradually increasing doses of specific allergens to eligible patients, with the objective of modifying the immune response and increasing tolerance to allergen exposure. The treatment is used for conditions including allergic rhinitis, allergic asthma, and insect-venom hypersensitivity, while oral immunotherapy has also expanded treatment options for selected food allergies.

Gain a preview of important insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=35708

Market Overview: The growth of the allergy immunotherapy industry is being supported by the increasing burden of allergic diseases, greater awareness of long-term treatment options, advances in allergen formulations, and improvements in allergy diagnosis. Unlike conventional medicines that primarily control symptoms, immunotherapy is designed to modify the underlying allergic response in appropriately selected patients.

North America held the largest regional revenue share in 2025, accounting for approximately 41.5% of the global market. The region benefits from established healthcare infrastructure, a large base of allergy specialists, greater patient awareness, clinical research activity, and access to innovative treatment options.

By treatment type, subcutaneous immunotherapy (SCIT) accounted for approximately 65.2% of market revenue in 2025, supported by its established clinical use and ability to address a broad range of environmental allergens.

Key Drivers of Market Growth

The rising prevalence of allergic diseases is one of the primary factors supporting market expansion. Allergic rhinitis, asthma, food allergies, insect allergies, and other hypersensitivity disorders affect populations across both developed and emerging markets. Urbanization, environmental changes, pollution, and changing patterns of exposure to allergens are among the factors associated with the increasing burden of allergic conditions.

Another important driver is the growing awareness of disease-modifying allergy treatments. Patients and healthcare professionals are increasingly recognizing the potential long-term benefits of immunotherapy when compared with treatments primarily intended to provide temporary symptom relief.

Advances in allergy diagnostics, standardized allergen extracts, clinical guidelines, and specialist allergy services are also improving patient identification and treatment access. The availability of sublingual immunotherapy (SLIT), including tablet-based approaches, has further broadened treatment options and may improve convenience for eligible patients.

Key Players and Industry Leaders

The global allergy immunotherapy market includes pharmaceutical, biotechnology, and specialty allergy companies developing and commercializing a range of immunotherapy products.

Prominent companies include ALK-Abelló A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy B.V., Worg Pharmaceuticals, DBV Technologies, Aimmune Therapeutics, ROXALL Medizin GmbH, Jubilant Pharma Limited, Aravax Pty Ltd, Merck KGaA, AllVac Pharmaceuticals, Inimmune Corporation, ALCIT INDIA PVT. LTD., Inmunotek, and Novartis AG.

Competition is increasingly focused on product innovation, clinical development, regulatory approvals, geographic expansion, partnerships, and the development of more convenient treatment formats.

Key Trends for the Future

Several trends are expected to influence the market through 2036. The adoption of SLIT is increasing because of its convenience and suitability for administration outside conventional injection-based clinical settings. At the same time, SCIT is expected to retain a significant position because of its established clinical evidence and broad allergen coverage.

The industry is also moving toward more targeted and personalized approaches, including standardized allergens, recombinant allergen research, improved formulations, and potentially biomarker-guided treatment strategies.

New Opportunities and Challenges

Increasing regulatory approvals for innovative immunotherapy products represent a major opportunity for market participants. Regulatory developments in major markets can enable companies to expand product portfolios, reach new patient populations, and enter additional geographic markets.

Growing investment in clinical trials and late-stage development could also contribute to the introduction of new products.

However, challenges remain. Allergy immunotherapy can require prolonged treatment periods, while treatment costs, patient adherence, healthcare access, and the need for appropriate patient selection can affect adoption. Maintaining treatment compliance over an extended period remains an important consideration for healthcare providers and manufacturers.

Access our report for a comprehensive look at key insights - https://www.transparencymarketresearch.com/allergy-immunotherapy-market.html

Market Trends & Innovations

Innovation is increasingly centered on improving safety, convenience, efficacy, and patient accessibility. SLIT tablets and other convenient formulations are gaining attention, while SCIT continues to benefit from standardized allergen extracts and extensive clinical experience.

Recent industry developments illustrate this innovation. In February 2024, ALK announced that the U.S. FDA expanded the indication for ODACTRA, a house dust mite allergen tablet, to include children aged 5–11 years in addition to previously covered age groups.

In July 2024, Stallergenes Greer announced FDA approval of Palforzia for children aged 1–3 years with confirmed peanut allergy, expanding the age range for this oral immunotherapy product.

In September 2025, Changchun GeneScience Pharmaceutical Co., Ltd. announced a partnership with ALK to develop and commercialize allergy immunotherapy products in China, including distribution rights for three ALK products in mainland China.

Future Outlook

The allergy immunotherapy market is expected to maintain steady growth through 2036 as allergic diseases become an increasing healthcare concern and demand rises for longer-term treatment approaches. The market is projected to increase from USD 2.8 billion in 2025 to USD 6.6 billion by 2036, representing an 8.1% CAGR during 2026–2036.

Expansion of allergy diagnostic services, increasing awareness, product innovation, regulatory approvals, and growing investment in research are expected to support market development. North America is anticipated to remain a major market, while opportunities across Europe, Asia Pacific, Latin America, and the Middle East & Africa are expected to expand alongside improvements in healthcare infrastructure.

Buy this Premium Research Report to access comprehensive analysis - https://www.transparencymarketresearch.com/checkout.php?rep_id=35708<ype=S

Market Segmentation

The global allergy immunotherapy market can be segmented as follows:

By Treatment Type:

Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), and Oral Immunotherapy.

By Allergy Type:

Allergic Rhinitis, Asthma, Food Allergy, Venom Hypersensitivity, and Others.

By Type of Allergen:

Pollens, Dust Mites, Mold, Bee Venom, and Others, including cat and dog allergens and cockroach allergens.

By Distribution Channel:

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Region:

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Important FAQs with Answers

Q. How large was the global allergy immunotherapy market in 2025?

The market was valued at approximately USD 2.8 billion in 2025.

Q. What is the projected market size by 2036?

The market is projected to reach approximately USD 6.6 billion by 2036.

Q. What is the expected CAGR?

The market is anticipated to expand at a CAGR of 8.1% from 2026 to 2036.

Q. What are the major growth drivers?

Key drivers include the rising prevalence of allergic diseases, increasing awareness of disease-modifying treatments, advances in immunotherapy products, improved allergy diagnostics, and growing healthcare access.

Q. Who are the prominent market players?

Major participants include ALK-Abelló A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy, Worg Pharmaceuticals, DBV Technologies, Aimmune Therapeutics, ROXALL Medizin, Jubilant Pharma, Aravax, Merck KGaA, Inmunotek, and Novartis, among others.

Explore Latest Research Reports by Transparency Market Research

Inflammatory Bowel Disease Treatment Market

Asthma and COPD Drugs Market

PCSK9 Inhibitor Market

Pet Care Diabetes Drugs Market

Immunotherapy Drugs Market

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analyzed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Media Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com